Market Overview

Innovus Pharma Announces Three Regulatory Filings with Health Canada for Its Products: Xyralid® Suppositories, Beyond Human® Testosterone and RecalMax™

Share:

The Three Potential Products, If Approved, Will Supplement the
Company's Eight Products Launched in Canada to Date

Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company") (OTCQB
Venture Market: INNV), an emerging commercial-stage pharmaceutical
company that delivers safe, innovative and effective over-the-counter
medicine and consumer care products to improve men's and women's health
and respiratory diseases, today announced the filing by it for
regulatory approval in Canada for its (1) Xyralid® Suppositories drug
for the relief of hemorrhoidal swelling, (2) Beyond Human® Testosterone
to promote and maintain testosterone levels in men and (3) RecalMax™ for
cognitive health and mental sharpness. The regulatory approval process
for the three products may take anywhere up to 210 days for approval
depending on the application.

"We are happy to announce our filing of applications with Health Canada
for our Xyralid® Suppositories, Beyond Human® Testosterone and
RecalMax™," said Dr. Bassam Damaj, the President and Chief Executive
Officer of Innovus Pharma. "We believe, if approved, these three
products will sell well in Canada for their indications and will then
represent the six, seventh and eighth products launched by us in Canada
through our own sales and marketing commercial efforts in addition to
our products ProtaGoRx™, Vesele®, Apeaz®, Xyralid® and AllerVarx™. When
combined with the other four products we have launched there already
through third-party distributors, including Zestra®, Zestra Glide® and
Uxor® (EjectDelay®) marketed by Orimed Pharma and UriVarx® through our
partnership with Acerus Pharmaceuticals Corporation, we may have in
total, in the near future, twelve of our products being marketed and
sold in Canada."

About Xyralid® Suppositories

Xyralid® Suppositories was filed as an OTC drug in Canada with the
indication to temporarily shrink hemorrhoidal tissue. Xyralid®
Suppositories temporarily relieve itching, burning and discomfort
associated with hemorrhoids and aid in protecting irritated anorectal
areas.

About Beyond Human® Testosterone

Beyond Human® Testosterone is a patented product filed in Canada as a
Natural Health Product with the indication to promote and maintain the
levels of testosterone in men, which often decline with normal aging.

About RecalMax™

RecalMax™ is a patented formulation of L-Arginine and L-Citrulline, in
combination with the natural absorption enhancer Bioperine®. RecalMax™
was filed in Canada as a Natural Health Product with the indication to
increase mental health and mental sharpness. The beneficial effects of
RecalMax™ on cognitive functions were confirmed in a four-month U.S.
clinical survey study involving 152 patients (69 men and 83 women).
Results from the clinical survey have indicated improvement in multiple
brain functions, including word recall and focus.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer
goods and specialty pharmaceutical company engaged in the
commercialization, licensing and development of safe and effective
non-prescription medicine and consumer care products to improve men's
and women's health and vitality and respiratory diseases. Innovus Pharma
delivers innovative and uniquely presented and packaged health solutions
through its (a) OTC medicines and consumer and health products, which we
market directly; (b) commercial partners to primary care physicians,
urologists, gynecologists and therapists; and (c) directly to consumers
through our on-line channels, retailers and wholesalers. The Company is
dedicated to being a leader in developing and marketing new OTC and
branded Abbreviated New Drug Application ("ANDA") products. The Company
is actively pursuing opportunities where existing prescription drugs
have recently, or are expected to, change from prescription (or Rx) to
OTC.

For more information, go to www.innovuspharma.com;
www.zestra.com;
www.ejectdelay.com;
www.myvesele.com;
www.urivarx.com;
www.sensumplus.com;
www.myandroferti.com;
www.beyondhumantestosterone.com;
www.getbeyondhuman.com;
www.trybeyondhuman.com;
www.recalmax.com;
www.prostagorx.com;
www.fluticare.com;
www.allervarx.com;
www.apeaz.com;
www.diabasens.com;
and www.xyralid.com.

Innovus Pharma's Forward-Looking Safe Harbor:

Statements under the Private Securities Litigation Reform Act, as
amended: with the exception of the historical information contained in
this release, the matters described herein contain forward-looking
statements that involve risks and uncertainties that may individually or
mutually impact the matters herein described for a variety of reasons
that are outside the control of the Company, including, but not limited
to, projected revenues from the potential three above products in
Canada, estimated market for its products, and statements about
achieving its other development, growth, commercialization, financial
and staffing objectives. Readers are cautioned not to place undue
reliance on these forward-looking statements as actual results could
differ materially from the forward-looking statements contained herein.
Readers are urged to read the risk factors set forth in the Company's
most recent filing on Form S-1, annual report on Form 10-K, subsequent
quarterly reports filed on Form 10-Q and other filings made with the
SEC. Copies of these reports are available from the SEC's website or
without charge from the Company.

View Comments and Join the Discussion!